HEC53856 not checked
Sunshine Lake Pharma Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The experimental cohort is divided into four groups: 20 mg once a day (QD) group, 40 mg QD group, 60 mg QD group, and 100 mg three times a week \[TIW\] group. Participants in the experimental cohort will take HEC53856 tablets orally either in the fasted state or after meals.”In the company’s words, NCT07891377 on ClinicalTrials.gov
- Tested for
- Chemotherapy-induced Anemia, Non-Myeloid Malignancy
- Main trialPhase 2
- “A Phase II clinical trial to evaluate the efficacy and safety of different dosing regimens of HEC53856 tablets compared to rHuEPO injection in participants of the CIA trial.”In the company’s words, NCT07891377 on ClinicalTrials.gov
Other drugs for Non-Myeloid Malignancy
- PEG-G-CSFKexing Biopharm Co., Ltd. · Phase 3
- Albipagrastim alfQilu Pharmaceutical · Phase 2
Coming up1
- Feb 2028Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials4
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Feb 2028 | HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies | |
| Phase 1Completed | 1 Jan 2020 | HEC53856 Phase 1 Study - Single and Multiple Oral Dosing in Healthy Volunteers | |
| Phase 1Completed | 19 Oct 2022 | Study of HEC53856 in Patients With Subjects With End-Stage Renal Disease Receiving Dialysis. | |
| Phase 1Completed | 29 Aug 2023 | HEC53856 Phase Ib Study in Patients With Non-dialysis Renal Anemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026